Icosavax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICVX research report →
Range $27 – $27
Price Chart
About the company
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses.
- CEO
- Adam K. Simpson
- IPO
- 2021
- Employees
- 60
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on ICVX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $769.04M
- P/E
- -6.87
- PEG
- -47.24
- P/S
- 1321.37
- P/B
- 2.79
- EV/EBITDA
- -7.63
- Div Yield
- 0.00%
- Gross Margin
- -216.67%
- Op Margin
- -16332.99%
- Net Margin
- -15198.97%
- ROE
- -35.64%
- ROIC
- -40.37%
Latest fiscal year · YoY change
- Revenue
- $582.00K-92.5%
- Gross Profit
- $-1,261,000-116.3%
- Op Income
- $-95,058,000
- Net Income
- $-88,458,000-30.1%
- EPS
- $-2.23+41.0%
- OCF Growth
- -60.0%
- FCF Growth
- -84.1%
- 52W High
- $16.11
- 52W Low
- $4.75
- 50D MA
- $14.98
- 200D MA
- $10.02
- Beta
- 1.28
- RSI (14)
- 55
- Avg Volume
- 1.05M
No earnings-call transcripts are available for ICVX yet.
- Free Float
- 58.3%
- Shares Outstanding
- 50.23M
- Float Shares
- 29.30M
of shares held by institutions
67 13F filers
Buy/sell ratio 0.06. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nanodimension, Inc. | 1.36M | ▼ 374.26K |
| Highland Private Wealth Management | 59.08K | 0 |
| Etf Managers Group, LLC | 12.96K | ▲ 12.96K |
Held by 2 ETFs
Biggest fund positions in ICVX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | sell | 17,000 |
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | other | 638,668 |
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | sell | 22,278 |
| Feb 19, 24 | Simpson Adam K. | other | 129,032 |
| Feb 19, 24 | Simpson Adam K. | sell | 317,866 |
| Feb 19, 24 | Simpson Adam K. | sell | 237,146 |
| Feb 19, 24 | Simpson Adam K. | sell | 375,000 |
| Feb 19, 24 | Simpson Adam K. | sell | 191,449 |
| Feb 19, 24 | Simpson Adam K. | sell | 1,347,546 |
| Feb 19, 24 | Simpson Adam K. | sell | 350,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ICVX coverage
Recent articles, reports, and earnings notes.
No research on ICVX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ICVX report →ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
prnewswire.com · Jan 26
ICVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Icosavax, Inc. Is Fair to Shareholders
businesswire.com · Jan 3
ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
businesswire.com · Dec 29
ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
businesswire.com · Dec 14
Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know
zacks.com · Dec 13
Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade
zacks.com · Dec 13
Why AstraZeneca Is Buying Icosavax For $1.1 Billion
investopedia.com · Dec 12
Shareholder Alert: Ademi LLP investigates whether Icosavax, Inc. has obtained a Fair Price in its transaction with AstraZeneca
prnewswire.com · Dec 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.